Clear Cell Renal Cell Carcinoma with Sarcomatoid Differentiation: A Case Report

Authors
Dr Supriya Verma¹, Dr Sarita Asotra²*, Dr V Anish Chandran³

¹Senior Resident, Department of Pathology, Indira Gandhi Medical College, Shimla
²Associate Professor, Department of Pathology, Indira Gandhi Medical College, Shimla
³Junior Resident, Department of Pathology, Indira Gandhi Medical College, Shimla

*Corresponding Author
Dr Sarita Asotra
Associate Professor, Department of Pathology, Indira Gandhi Medical College, Shimla,
Himachal Pradesh- 171001, India

Abstract
Renal cell carcinoma (RCC) with sarcomatoid differentiation belongs to most aggressive clinicopathologic type of RCC. It is associated with poor prognosis and therapeutic outcome. We report a case of clear cell renal cell carcinoma with sarcomatoid differentiation involving left kidney in a 51 year old female. Immunohistochemistry was performed for exact characterization. The importance of this case report is identification and reporting of sarcomatoid component in renal cell carcinoma as it confers more propensity of metastasis and hence less chances of survival.

Keywords: renal cell carcinoma (RCC), sarcomatoid differentiation, poor prognosis.

Introduction
RCC with sarcomatoid differentiation is an aggressive form of RCC characterized by high propensity of metastasis and poor outcome with limited therapeutic options[1]. We report a case of clear cell renal cell carcinoma with sarcomatoid differentiation in a 51 year old female.

Case Report
A 51 years old female presented with complaints of pain in left lumbar region, hematuria and burning micturition. Patient was non diabetic and non hypertensive. USG abdomen revealed enlarged kidney measuring 12.7x5.9 cm with large heteroechoic mass involving mid and lower pole of left kidney measuring 7x6x5.7 cm partially extending into renal sinus and reaching upto renal hilus. Pelvicalyceal system was not dilated. Urine cytology revealed albumin, pus cells and RBCs. Serum creatinine was increased and uric acid was within normal limits. Patient underwent left radical nephrectomy. The specimen was sent for histopathological examination. Immunohistochemistry was also performed for confirmation and exact characterization. Sections from tumour showed round to polygonal tumour cells with round vesicular nuclei, conspicuous to prominent nucleoli, occasional mitotic activity, moderate to abundant clear to pale eosinophilic cytoplasm arranged in acini, nests, pseudopapillae [Figure 1] and separated by fibro vascular septa [Figure 2]. In addition, sarcomatoid areas were seen comprising less than 50% of tumour [Figure 3] and showing atypical spindle cells with mild pleomorphism in poorly formed fascicles arranged around vessels [Figure 4]. Mitotic index was 5 per 10 HPF (high power field). Focal areas showed hemorrhage, necrosis, lymphocytic infiltrate, mast cells, marked hyalinization and dystrophic calcification. Renal
capsule, perinephric fat, hilar vessels and ureter were free from tumour invasion. Immunohistochemistry showed positivity for vimentin in sarcomatous component [Figure 5A & 5B] and CD10 in epithelial component [Figure 6A & 6B].

**Figure 1:** Photomicrograph showing tumor epithelial cells arranged in acini and nests with clear cytoplasm (H&E, x400)

**Figure 2:** Photomicrograph showing tumour epithelial cells (right) separated by fibrovascular septa and a focus showing sarcomatoid component (left) (H&E, x100)

**Figure 3:** Photomicrograph showing sarcomatoid component occupying less than 50% of the tumour (H&E, x100)

**Figure 4:** Photomicrograph showing sarcomatoid component with atypical spindle cells having mild pleomorphism (H&E, x400)

**Figure 5A & 5B:** Immunohistochemistry: Vimentin showing cytoplasmic positivity in sarcomatous component
Figure 6A & 6B: Immunohistochemistry: CD 10 showing membrane positivity in neoplastic epithelial cells

Discussion
RCC with sarcomatoid differentiation belong to the most aggressive clinicopathologic phenotypes of RCC. It is characterized by high chances of metastasis and limited therapeutic modalities, as it is resistant to already established systemic targeted therapy. Most studies report a poor median survival of 5 to 12 months\(^1\).

Sarcomatoid differentiation is seen in 5-8% of clear cell RCC, 8-9% of chromophobe RCC and 2-3% of papillary RCC\(^2,3\). The term “sarcomatoid RCC” is not a distinct morphogenetic subtype of RCC as it occur with all histologic subtypes. It originates from epithelial- mesenchymal transition and thus shows both epithelial (carcinoma) and mesenchymal (sarcomatoid) components on morphological and immunohistochemical level\(^4\). This feature differentiates it from primary sarcoma of kidney\(^5\).

The presence of even a small component of sarcomatoid differentiation was shown to independently predict poor survival and outcome compared to RCC without sarcomatoid features. Thus, it is very important to describe this differentiation in surgical pathology report\(^6\). Dall Oglio MF et al compared outcome of individuals with pure sarcomatoid tumour with that of sarcomatoid differentiation in clear cell carcinoma. Although sarcomatoid RCC is commonly associated with high grade tumours, it can also be seen with low grade tumours\(^7\). However, greater than 50% of this component is associated with worse survival which is contested by Bertoni et al. He also states that patients with low Fuhrman nuclear grade and less than 5% of sarcomatoid differentiation have much better chances of cure\(^8\). The frequency of sarcomatoid tumours with high Fuhrmans nuclear grade is 64-100%\(^3\).

In early half of 20\(^{th}\) century, renal tumors with sarcoma like features were characterized by pathologists as “renal sarcomas”. Later many pathologists began to recognize classic RCC characteristics in many of these tumours. It lead to a change in nomenclature of renal sarcomas to a different term “carcinosarcoma” of kidney. Eventually, the term “sarcomatoid RCC” was established and was considered a separate histologic type because of it’s highly aggressive nature. However, a separate subtype for sarcomatoid carcinoma was challenged by pathologists with recognition of sarcomatoid changes in association with almost every histologic type of renal tumour\(^9\).

Histologic characteristics of sarcomatoid RCC show features similar to sarcomas with spindle like cells, high cellularity and cellular atypia. Regions of sarcomatoid differentiation do not have noticeable epithelial components. Common histologic patterns can resemble fibrosarcoma or malignant fibrous histiocytoma, osteoid or chondroid differentiation. Additional poor prognostic factors such as necrosis and microvascular invasion are present in 90% and...
30% cases respectively\(^6\). Majority of tumours have a variable carcinoma component. If absent, the pathologist should consider cutting additional tumour blocks for a more thorough assessment.
Among epithelial component, clear cell RCC is most commonly associated with sarcomatoid differentiation (greater than 80% cases). Undifferentiated RCC accounts for 2-10% of sarcomatoid RCC\(^10\). However, some studies have shown that chromophobe RCC has highest association with sarcomatoid features\(^11\).

It is important to differentiate between classic sarcoma and sarcomatoid RCC. Primary renal sarcomas are extremely rare in adults accounting for less than 1% of renal malignancies and most of them are leiomyosarcoma which contain smooth muscle components that are rarely seen in sarcomatoid RCC\(^12\). In addition, primary renal sarcomas should not contain any classic areas of RCC\(^6\). Other mimickers of sarcomatoid RCC are sarcomatoid urothelial tumours. They may be distinguished by presence of flat in situ areas and/or squamous differentiation.

For confirmation of diagnosis of sarcomatoid RCC, additional tests like electron microscopy and immunohistochemistry (IHC) may be performed. Electron microscopy show epithelial components (such as desmosomes or basal lamina) which may not be observed by classic light microscopy\(^13\). IHC for common epithelial and mesenchymal markers may distinguish sarcomatoid RCC from sarcoma. A review by Delong and colleagues demonstrated that sarcomatoid areas express cytokeratin AE1/AE3 and vimentin in 97% and 56% of cases respectively\(^14\). Classic markers of mesenchymal tissue and sarcomas, eg-desmin and actin are infrequently expressed in sarcomatoid RCC.
Kanamaru and colleagues demonstrated that sarcomatoid component had a higher Ki-67 expression level and proliferative activity than the carcinoma\(^15\).

RCC with sarcomatoid differentiation are large, with mean tumour size of 9-10 cm and 90% are symptomatic. Metastatic rate is extremely high at presentation with 45-84% having evidence of systemic disease\(^16\). Most common sites of metastasis are lungs, bone, lymph nodes, liver and brain\(^7\).

Sarcomatoid RCC is often treated by surgery as conventional RCC because there is no reliable test to diagnose sarcomatoid differentiation preoperatively. It appears that sarcomatoid RCC shows less desirable response to systemic therapy than RCC with non-sarcomatoid differentiation. Some authors suggest that immunotherapy has less favorable results than chemotherapy and anti-angiogenesis targeted therapy. Surveillance after radical treatment should be based upon risk stratification in these tumors\(^18\).

**Conclusion**

RCC with sarcomatoid differentiation is an aggressive tumor associated with disease progression and poor prognosis. Aggressive treatment strategies and close surveillance are required while dealing with these tumors.

**References**

4. Mikami S., Katsube K., Oya M., Ishida M., Kosaka T., Mizuno R., Mukai M.,


